Inmed pharmaceuticals completes acquisition of baymedica creating a market leader in the manufacturing of rare cannabinoids

Vancouver, british columbia and south san francisco, calif., oct. 13, 2021 (globe newswire) -- inmed pharmaceuticals inc. (“inmed” or the “company”) (nasdaq: inm), a leader in the manufacturing and clinical development of rare cannabinoids, today announced that they have completed the previously announced acquisition of baymedica inc. (“baymedica”), a private company based in the us specializing in the manufacturing and commercialization of rare cannabinoids for the health and wellness sector.
INM Ratings Summary
INM Quant Ranking